MAPT and Alzheimer disease: A phase II trial is now running with MCI to mild AD with serum and CSF neuroinflammatory cytokines dosage (IL-1, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL13, IFNγ, TNF-α, TGFβ), T- and B-lymphocytes’ quantitation, plasma and CSF NfL, plasma and CSF Aβ1-42/Aβ1-40, CSF t-tau and p-tau, CSF YKL-40 concentrations as secondary outcomes (results not available) [167,168].